Skip to main content
. 2015 May 19;2015:159269. doi: 10.1155/2015/159269

Table 1.

MDSCs-mediated refractoriness to chemotherapy or radiotherapy.

Treatment Mechanisms References
Anti-VEGF antibody (bevacizumab) Bv8 production in MDSCs [118]

Anthracycline/cyclophosphamide S100A8/9 production in accumulated MDSCs via secretion of CXCL1/2 by cancer cells [8]

Tyrosine kinase inhibitor (sunitinib) Bv8 production in MDSCs
pSTAT5-dependent pathway via GM-CSF production
[118, 119]

Radiotherapy G-CSF-mediated MDSC accumulation [120]